peptide garden
Peptide Profile

Petrelintide

Petrelintide (ZP8396)

An investigational once-weekly amylin analog from Zealand Pharma, partnered with Roche. Published Phase 2 results support weight loss, with nausea higher than placebo. No Phase 3 results or FDA approval.

Reviewed October 1, 2026·16 min read·18 citations·Not approvedPhase 3 registered

At a glance

Petrelintide is a once-weekly amylin analog -- a peptide that works through a different pathway than the GLP-1 drugs everyone is talking about. It is not FDA-approved. On September 28, 2026, ClinicalTrials.gov posted ZUPREME-3, a 3,900-participant Phase 3 monotherapy study; it is not yet recruiting, its estimated start is September 30, and it has no results.[14] Its headline Phase 2 result: up to 10.7% weight loss vs 1.7% placebo at 42 weeks, with nausea higher than placebo and low rates of vomiting. It is developed by Zealand Pharma and partnered with Roche (Genentech in the US).

Animal studiesModerateClass mechanism characterized

Petrelintide-specific engineering and preclinical pharmacology were published in the 2025 development report, alongside the established amylin-class mechanism. Animal findings do not establish human effectiveness.

Human evidenceModerate485 treated in Phase 2

Published randomized Phase 2 results; no Phase 3 results or FDA approval.

Safety dataModerate485 treated in Phase 2

Published Phase 2 safety; nausea exceeded placebo. Long-term and comparative tolerability remain unknown.

How are these scores calculated?

Petrelintide is an investigational drug -- it has not been approved by the FDA or any regulatory agency. What that means: ZUPREME-1 and the Phase 1 studies are now peer-reviewed, but Phase 3 has no results and long-term safety is unknown. It is not available by prescription or at pharmacies.

New research, delivered clearly

When new studies publish or clinical trials report results, we'll break them down in plain language.

Quick facts

Drug class
Amylin analog (amylin receptor agonist)
Molecular weight
~4,191.8 g/mol (reported)
Amino acid sequence
See published development report
Dosing
Once weekly, subcutaneous
Developer
Zealand Pharma (partnered with Roche)
FDA status
Not approved (Phase 3 registered; not yet recruiting)

What is petrelintide?

Petrelintide is a synthetic, long-acting amylin analog -- a peptide designed to mimic amylin, a hormone your pancreas releases alongside insulin after you eat.[7] It is given as a once-weekly subcutaneous injection and is being developed for chronic weight management. Its research code is ZP8396.

The compound originated at Zealand Pharma in Denmark. In March 2025, Roche entered an exclusive collaboration to co-develop and co-commercialize petrelintide; Genentech is the Roche Group's US member, which is why you will sometimes see the program described as "Roche/Genentech."[4] This matters because it puts a large pharmaceutical company's resources behind a Phase 3 program -- but it does not change the regulatory reality: petrelintide is not approved anywhere.

What makes petrelintide notable is the pathway it uses. Most of the headline weight-loss drugs -- semaglutide, tirzepatide, retatrutide -- are built around GLP-1 (and sometimes GIP and glucagon) receptors. Petrelintide instead targets amylin receptors, a complementary mechanism. Its closest direct comparator is cagrilintide, the other leading long-acting amylin analog.

Important: Petrelintide is not FDA-approved and is not available by prescription, at pharmacies, or through compounding. It is only available through enrollment in clinical trials. Any commercial sale of petrelintide is unauthorized. It is not partnered with Metsera, and it is not on the July 2026 FDA Pharmacy Compounding Advisory Committee agenda.

A note on identity details: The petrelintide-specific development report was published in 2025, and published Phase 1 trials report a half-life of approximately 10 days. We have not curated the sequence from the development paper here. Formula and mass shown above remain reported registry values.[18][16]


How it works

In plain terms, petrelintide mimics amylin, a "fullness" hormone. After a meal, your body releases amylin along with insulin; amylin tells your brain you have eaten enough, slows how quickly food leaves your stomach, and helps restore your sensitivity to leptin (another satiety hormone that often stops working well in obesity).[7]

This is a different lever than GLP-1 drugs pull. GLP-1 agonists reduce appetite primarily through their own receptor pathway; amylin works largely through the area postrema, a region of the brainstem that senses satiety signals. Because the two pathways are separate but related, they appear to add together -- which is the entire rationale for combination products in this space.[9]

Detailed mechanism (for advanced readers)

Petrelintide is a long-acting amylin receptor agonist. Native human amylin (also called IAPP) is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors -- heteromers of the calcitonin receptor paired with receptor-activity-modifying proteins (RAMPs).[7]

Core effects of amylin receptor agonism:

  • Satiety signaling: Amylin binds receptors concentrated in the area postrema of the brainstem, which relays to the lateral parabrachial nucleus to suppress appetite.
  • Slowed gastric emptying: Food leaves the stomach more slowly, prolonging fullness after meals.
  • Restored leptin sensitivity: Amylin appears to re-sensitize the brain to leptin, a hormone whose signaling is often blunted in obesity. This is thought to be central to durable appetite control.

Why a long-acting analog: Native amylin has a very short half-life and a tendency to aggregate, making it impractical as a once-weekly drug. Long-acting amylin analogs are engineered for stability and extended exposure suitable for weekly dosing -- the same design challenge solved for cagrilintide.[8] Petrelintide-specific engineering and pharmacology are described in its published development report.[18]

Complementary to GLP-1 (the combination thesis): A Phase 1b study of cagrilintide plus semaglutide showed that adding an amylin analog to a GLP-1 agonist produced greater weight loss than either alone, with the two mechanisms acting additively on appetite.[9] Roche and Zealand are pursuing this strategy directly, developing petrelintide in combination with Roche's incretin agent enicepatide (CT-388).[4]

The strategic bet: Because amylin agonism tends to produce less nausea and vomiting than GLP-1 agonism, petrelintide's developers are positioning it as a better-tolerated foundation -- a drug people can actually stay on -- rather than a maximum-efficacy agent.


What the research says

Published Phase 2 evidence supports meaningful weight loss, with nausea higher than placebo. Phase 3 has no results, and no head-to-head study establishes better tolerability than a GLP-1 medicine.

Peptide Garden evidence assessment, October 2026

Research timeline

Petrelintide moved from early clinical work to a Phase 3 decision in roughly two years:

  1. 2024Human study

    Early clinical signal

    Zealand Pharma reports early-phase weight-loss data for ZP8396 (petrelintide) as a once-weekly amylin analog, supporting advancement into larger Phase 2 trials.

  2. 2025Human study

    Roche partnership and Phase 2 enrollment

    March 2025: Roche enters an exclusive collaboration to co-develop and co-commercialize petrelintide. The Phase 2b ZUPREME-1 (obesity, no T2D) and ZUPREME-2 (obesity + T2D) trials enroll.

  3. 2026Human study

    ZUPREME-1 topline and full ADA readout

    March 5, 2026: ZUPREME-1 meets its primary endpoint (up to 10.7% weight loss vs 1.7% placebo). June 5, 2026: detailed data presented at ADA 2026 — placebo-like GI tolerability, broad cardiometabolic improvements.

  4. 2026Human study

    ZUPREME-3 Phase 3 study registered

    April 2026: partners announced a Phase 3 chronic-weight-management program. On September 28, 2026, ClinicalTrials.gov posted ZUPREME-3 (NCT07843498): 3,900 planned participants, placebo-controlled monotherapy, 64-week primary endpoint. It is not yet recruiting, has an estimated September 30 start, and has no results. The next catalysts are ZUPREME-2 topline (obesity + T2D) and the start of ZYNERGY, the Phase 2 trial of petrelintide combined with Roche's enicepatide.

Human clinical trials

Petrelintide now has published Phase 1 and randomized Phase 2 evidence; there are no Phase 3 results.

ZUPREME-1 (the readout that matters): A Phase 2b trial in people with overweight or obesity without type 2 diabetes. It randomized 493 participants across 32 sites; 485 received treatment. The treatment period was 42 weeks (dose escalation up to 16 weeks), with safety follow-up to week 51 and the primary endpoint assessed at week 28. The population was 53% female, mean age 47, mean BMI 36.7 kg/m², and baseline weight 107.1 kg.[1]

ZUPREME-2 (completed; no results posted): A Phase 2b trial in people with overweight or obesity and type 2 diabetes, testing three doses up to 9 mg over 28 weeks. The registry was updated September 9, 2026 to completed, without posted results.[5]

2026·Phase 2b, double-blind, randomized, placebo-controlled (5:1)·n=493Moderate quality

ZUPREME-1: Petrelintide for overweight or obesity (no T2D)

Overweight or obesity without type 2 diabetes

Published ZUPREME-1 (Lancet Diabetes & Endocrinology, September 29, 2026): 493 randomized and 485 treated. The primary endpoint was weight change at week 28, ranging from -7.9% to -9.8% across doses versus -1.7% placebo; weight reduction reached up to 10.7% at week 42. Nausea occurred in 20% versus 6%, vomiting in 3% versus 6%, and no deaths were reported. This remains Phase 2 evidence.

2026·Phase 2b, double-blind, randomized, placebo-controlled·n=N/ALow quality

ZUPREME-2: Obesity with type 2 diabetes (completed; no results)

Overweight or obesity with type 2 diabetes

The registry update dated September 9, 2026 lists NCT06926842 as completed. No results are posted; completion is not efficacy evidence.

2026·Phase 3, quadruple-masked, randomized, placebo-controlled·n=N/ALow quality

ZUPREME-3: Petrelintide monotherapy (registered, not yet recruiting)

Overweight or obesity without type 2 diabetes

ClinicalTrials.gov posted this monotherapy study (NCT07843498) on September 28, 2026. It plans 3,900 participants, has an estimated September 30 start, and measures percent weight change through week 64. It is not yet recruiting and has no results.

2026·Phase 2, dose-finding, fixed-dose combination·n=N/ALow quality

ZYNERGY: Petrelintide + enicepatide combination (registered, not started)

Obesity or overweight

A registered but not-yet-recruiting trial (NCT07589686) testing petrelintide in a fixed-dose combination with enicepatide, Roche's GLP-1/GIP dual agonist. 486 participants planned, sponsored by Hoffmann-La Roche, with a September 2026 start date. This is the combination the Roche–Zealand partnership was built around. No data exist.

The combination trial to watch: ZYNERGY

The most interesting thing on petrelintide's near-term calendar is not the monotherapy Phase 3 — it is ZYNERGY, a Phase 2 trial pairing petrelintide with enicepatide, Roche's GLP-1/GIP dual agonist (previously known as CT-388).[12]

The reasoning is the same one behind CagriSema: amylin and incretin biology work through different pathways, so combining them should produce more weight loss than either alone.[9] What makes this particular pairing worth watching is the specific bet — petrelintide's unusually mild side-effect profile combined with an incretin's efficacy, aiming for high weight loss that people can actually tolerate.

Keep the status straight, though. At the October 1, 2026 check the trial remained registered with a September 2026 start date and had not begun enrolling. It is a Phase 2 dose-finding study of 486 people. There are no results, and there will not be for some time.

Where the evidence stands: ZUPREME-1 is now published. It randomized 493 people; 485 received treatment. Its primary weight endpoint was at week 28, with follow-up through week 42. Phase 1 results are also published. ZUPREME-2, ZYNERGY and ZUPREME-3 have no reported results.[15][16]


What the evidence shows

Petrelintide has attracted attention as a potentially gentler weight-loss drug. Here is what the Phase 2 data actually supports -- and what it does not:

Does petrelintide produce meaningful weight loss?

Published ZUPREME-1 (Lancet Diabetes & Endocrinology, September 29, 2026): 493 randomized and 485 treated. The primary endpoint was weight change at week 28, ranging from -7.9% to -9.8% across doses versus -1.7% placebo; weight reduction reached up to 10.7% at week 42. Nausea occurred in 20% versus 6%, vomiting in 3% versus 6%, and no deaths were reported. This remains Phase 2 evidence.

Well-supported

Does petrelintide have better GI tolerability than GLP-1 drugs?

ZUPREME-1 reports relatively low gastrointestinal event rates except nausea (20% versus 6% placebo). It was not a head-to-head trial against a GLP-1 drug, so comparative tolerability remains unproven.

More research needed

Does petrelintide improve cardiometabolic risk factors?

Yes, in Phase 2 secondary endpoints. ZUPREME-1 reported waist-circumference reductions of 7.9–10.8 cm (vs 4.3 cm placebo), high-sensitivity C-reactive protein (hsCRP) reductions of 17–41% (vs 6%), and triglyceride reductions of 12–21% (vs 9%). These are secondary endpoints from a single Phase 2 trial and are largely attributable to weight loss; dedicated cardiovascular-outcomes data do not exist.

Well-supported

Is petrelintide as effective as GLP-1 drugs for weight loss?

No head-to-head trial establishes equivalent or superior weight loss to a GLP-1 medicine. Cross-trial comparisons cannot answer that question.

More research needed

Does petrelintide work in type 2 diabetes?

Unknown. ZUPREME-1 enrolled people without type 2 diabetes. ZUPREME-2 (NCT06926842) is completed according to its September 9 registry update, but no results are posted. Completion alone does not establish efficacy.

More research needed

Can you buy or be prescribed petrelintide now?

No. Petrelintide is investigational and not FDA-approved. It is not available by prescription, at pharmacies, or through compounding, and it is only accessible through clinical trial enrollment. ZUPREME-3 (NCT07843498), the monotherapy Phase 3 study, was posted on September 28, 2026 but is not yet recruiting and has no results. Since a Phase 3 obesity programme typically runs well over a year before it reports, the earliest plausible approval is several years away. Any website or supplier offering petrelintide for sale is operating outside regulatory boundaries.

Not yet demonstrated

Safety & side effects

What the Phase 2 trial shows

Published ZUPREME-1 safety results cover 485 treated participants. Nausea was more common than with placebo; vomiting and diarrhea rates were low. These are Phase 2 results without a direct GLP-1 comparator.[15]

Gastrointestinal events (ZUPREME-1, petrelintide vs placebo):

  • Nausea: 19.6% vs 6.2% placebo -- elevated, but less than half the rate commonly reported with GLP-1 agonists
  • Vomiting: 3.0% vs 6.2% placebo -- notably, lower than placebo
  • Diarrhea: under 7.5% (both arms)
  • Constipation: under 7.5% (both arms)
  • More than 75% of GI adverse events were mild

Reading the tolerability data honestly: It would be wrong to say petrelintide caused "no vomiting" or "no GI discontinuations." It did -- vomiting occurred in 3.0% of participants, and 1.5% discontinued because of GI side effects. The accurate framing is that the GI burden was low and close to placebo, with vomiting actually below the placebo rate. That is still a meaningful contrast with the nausea and vomiting that lead many people to stop GLP-1 drugs -- but it is "placebo-like," not "zero."

What this means in context

The developers' explicit pitch is adherence. Zealand's leadership framed the goal as "double-digit weight loss with placebo-like tolerability" -- a "sweet spot" for a first-choice medicine that people can actually stay on, rather than the highest possible number on the scale.[6] Analysts were split: some had expected higher efficacy (over 12%), and Eli Lilly's competing amylin candidate reached roughly 16% in its own Phase 2.[6] Whether tolerability or raw efficacy wins is a genuine open question.

What we don't know about safety

There are large gaps in the petrelintide safety picture:

  • Published early-phase data: ZUPREME-1 and the Phase 1 studies are peer-reviewed; this does not provide long-term or Phase 3 safety.
  • No long-term data: The longest exposure is the 42-week ZUPREME-1 treatment period (safety follow-up to week 51). Chronic-use safety is unknown.
  • No Phase 3 results or post-marketing data: ZUPREME-3 is registered but not yet recruiting; no large registrational dataset or real-world surveillance exists.
  • No T2D safety profile yet: ZUPREME-2 has not reported.
  • Lean mass and body composition: The quality of weight lost (fat vs lean mass) has not been detailed publicly.
  • No pregnancy or drug-interaction data: Not characterized.
  • Amylin-class effects: Long-term effects of sustained amylin receptor agonism in humans are less established than for the GLP-1 class.

As of August 2026:

FDA status

Petrelintide is not FDA-approved for any indication. It is an investigational drug that has completed Phase 2 testing.

  • No approved petrelintide product: It is not a component of any FDA-approved drug and has not been found safe and effective for any condition.
  • No Breakthrough or other designation publicly announced. Investigational status is a development stage, not a form of approval.
  • Not on the July 2026 PCAC agenda: The FDA Pharmacy Compounding Advisory Committee is not reviewing petrelintide.
  • Timeline: A Phase 3 chronic-weight-management programme was announced in April 2026 for initiation in the second half of the year.[3] ClinicalTrials.gov posted ZUPREME-3 (NCT07843498) on September 28, 2026: a 3,900-participant, placebo-controlled monotherapy study with an estimated September 30 start. It is not yet recruiting and has no results.[14] This is worth stating plainly because a registered Phase 3 trial is not a result or an approval. Phase 3 trials plus FDA review typically take several years from the day enrollment opens, so the earliest plausible approval is well beyond 2027.

How to access petrelintide today

The only legal way to access petrelintide is through enrollment in a clinical trial. Trial listings can be found at ClinicalTrials.gov by searching "petrelintide" or "ZP8396."[5]

For more on why a Phase 2/3 investigational drug cannot be legally compounded, see Why Investigational Peptides Are Not Compoundable.

Warning: Any website, pharmacy, or supplier offering petrelintide for sale is operating outside regulatory boundaries. The drug has not been approved, cannot be legally prescribed, and cannot be legally compounded. Research-grade peptides sold online are unregulated and may not contain what they claim.[10]

WADA / anti-doping status

Petrelintide is not specifically named on the 2026 WADA Prohibited List, and amylin analogs are not currently listed as a class. As an investigational, non-approved substance, it could fall under S0 (Non-Approved Substances) for athletes in some jurisdictions. This is an interpretation, not an official WADA classification.


How petrelintide compares

Petrelintide's natural comparators are other amylin analogs (cagrilintide) and the GLP-1/incretin drugs it is positioned against (tirzepatide, semaglutide). No head-to-head trials exist, so these comparisons rely on cross-trial data, which has serious limitations:

Petrelintide

Not approved · Amylin analog

Weight loss (Phase 2)~10.7%
GI tolerabilityPlacebo-like
CV outcomes dataNone
Evidence maturityPhase 2

Mechanism

Amylin

Dosing

Weekly SC

Approved for

None (Ph 2)

Compounding

Not available

Cagrilintide

Not approved (solo) · Amylin analog

Weight loss (Phase 2)~10–11%
GI tolerabilityFavorable
CV outcomes dataNone
Evidence maturityPh 2 / combo Ph 3

Mechanism

Amylin

Dosing

Weekly SC

Approved for

None

Compounding

Not available

Tirzepatide

FDA-approved · GIP/GLP-1 agonist

Weight loss (max dose)20–22%
GI tolerabilityGI-heavy
CV outcomes dataPending
Evidence maturityApproved

Mechanism

GIP+GLP-1

Dosing

Weekly SC

Approved for

3 indications

Compounding

Not permitted

The key tradeoffs:

  • Weight loss: Tirzepatide leads decisively in cross-trial terms (20–22% vs petrelintide's ~10.7%). Petrelintide is in the same range as cagrilintide as a solo amylin analog. But petrelintide is investigational and these are not head-to-head comparisons.[1]
  • Tolerability: This is petrelintide's argument. Its placebo-like GI profile -- including vomiting below placebo -- contrasts with the nausea and vomiting that drive many people off GLP-1 and incretin drugs.[1][6]
  • Combination potential: Amylin analogs add to GLP-1 agonists. Roche plans to combine petrelintide with its incretin enicepatide (CT-388), aiming to stack petrelintide's tolerability onto incretin-level efficacy.[4][9]
  • Evidence and availability: Tirzepatide is FDA-approved with a large evidence base; petrelintide has one Phase 2 readout and is not available outside trials.

The bottom line: petrelintide is a credible, well-tolerated amylin analog with a single promising Phase 2 trial behind it. Its real test -- both as a standalone weekly drug and as a combination partner -- remains ahead: the monotherapy Phase 3 trial is registered but not yet recruiting, and it has no results. Until then, petrelintide is investigational, and the numbers above should be read as early signals, not settled facts.



References

  1. [1]
    Zealand Pharma A/S. “New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity.” 2026. LinkRCT

    Historical sponsor presentation at ADA 2026; 493 randomized and 485 treated. Up to 10.7% weight reduction at week 42. The peer-reviewed Phase 2 report was subsequently published September 29, 2026 and is the preferred evidence source.

  2. [2]
    F. Hoffmann-La Roche Ltd. “Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity.” 2026. LinkRCT

    Topline ZUPREME-1 readout (March 5, 2026). Met primary endpoint with up to 10.7% mean weight loss vs 1.7% placebo and placebo-like GI tolerability. Predates the detailed ADA 2026 presentation.

  3. [3]
    Zealand Pharma A/S. “Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management.” 2026. LinkReview

    April 29, 2026 announcement that the partners will advance petrelintide into a Phase 3 chronic-weight-management program, with initiation planned for the second half of 2026.

  4. [4]
    F. Hoffmann-La Roche Ltd. “Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight or obesity.” 2025. LinkReview

    March 12, 2025 collaboration announcement. US + Europe co-developed and co-commercialized (50/50 profit/loss); Roche exclusive rest-of-world. Genentech is Roche's US member. Combination development planned with enicepatide (CT-388).

  5. [5]
    Zealand Pharma A/S. “Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2).” 2025. LinkRCT

    Registry rechecked October 1, 2026: completed, September 9 update, no posted results. Do not infer efficacy from status.

  6. [6]
    Hayden D. “ADA: Obesity partners Zealand and Roche aim for weight loss 'sweet spot' with amylin agonist.” BioSpace. 2026. LinkReview

    Independent ADA 2026 coverage. Captures analyst skepticism (William Blair expected >12%; Lilly's eloralintide ~20% in Phase 2) alongside the company 'tolerability sweet spot' framing. Provides honest cross-trial comparison context.

  7. [7]
    Boyle CN, Lutz TA, Le Foll C. “Amylin — Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.” Mol Metab. 2018. 8:203–210 DOI PubMedReview

    Foundational review of amylin physiology: area postrema signaling, satiety, slowed gastric emptying, and restoration of leptin sensitivity — the class mechanism petrelintide belongs to.

  8. [8]
    Kruse T, Hansen JL, Dahl K, et al.. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” J Med Chem. 2021. 64(15):11183–11194 DOI PubMedIn vitro

    Medicinal-chemistry context for long-acting amylin analogue design (the class to which petrelintide belongs). Petrelintide's own peptide-engineering paper is not yet published; its sequence and full structure remain undisclosed.

  9. [9]
    Enebo LB, Berthelsen KK, Kankam M, et al.. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.” Lancet. 2021. 397(10286):1736–1748 DOI PubMedRCT

    Demonstrates additive/complementary weight loss when an amylin analogue is combined with a GLP-1 agonist — the rationale behind petrelintide + enicepatide (CT-388) combination development.

  10. [10]
    U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

    FDA safety communication on unapproved weight-loss peptides sold online (research-use labeling, no human-consumption disclaimers). Used to frame why an investigational amylin analogue like petrelintide cannot be legally compounded or purchased.

  11. [11]
    Zealand Pharma A/S. “Zealand Pharma Announces Financial Results for the First Half of 2026.” 2026. LinkReview

    Company half-year report, August 13, 2026, accessed via the MFN regulatory-filing service. Confirms that petrelintide monotherapy Phase 3 initiation is still guided to the second half of 2026 and has not yet occurred, and lists ZUPREME-2 topline and initiation of the ZYNERGY combination trial as the next catalysts. No discontinuations reported.

  12. [12]
    ClinicalTrials.gov. “NCT07589686: A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight.” 2026. LinkRegistered trial (no results)

    Registry record for the ZYNERGY Phase 2 combination trial of petrelintide plus enicepatide. 486 participants planned, sponsored by Hoffmann-La Roche, not yet recruiting, start date September 2026. A trial registration, not a result.

  13. [13]
    Fischer SL, Borner T. “Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.” Pharmacol Res. 2026. 232:108382 DOI PubMedReview

    Narrative review of the amylin class (cagrilintide, eloralintide, petrelintide, NN1213) from a lab that studies the hindbrain circuitry involved. Its central argument is directly relevant to the tolerability question: whether an amylin analog is selective for the amylin receptor or also engages the calcitonin receptor may determine whether reduced food intake reflects physiological satiation or aversive signalling. A review, not new data. The senior author receives Novo Nordisk research funding not used for this work.

  14. [14]
    ClinicalTrials.gov. “NCT07843498: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity (ZUPREME-3).” 2026. LinkRegistered trial (no results)

    Official registry record, posted September 28, 2026. Phase 3, quadruple-masked, randomized, placebo-controlled monotherapy study; 3,900 participants planned; not yet recruiting; estimated start September 30, 2026; primary outcome percent weight change through week 64. A registration, not a result or evidence of benefit or safety.

  15. [15]
    Garvey WT, Ard J, Connery L, et al.. “Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.” Lancet Diabetes Endocrinol. 2026. DOI PubMedRCT

    Zealand-funded randomized Phase 2 report, published September 29, 2026; 493 randomized and 485 treated. Primary endpoint at week 28; extension results at week 42. Missing-at-random assumption and no Phase 3 results limit certainty.

  16. [16]
    Brændholt Olsen M, Griffin J, Hövelmann U, et al.. “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.” Diabetes Obes Metab. 2026. DOI PubMedPilot study

    Two Zealand-funded randomized Phase 1 studies published April 22, 2026. Early safety and pharmacology, not long-term safety or comparative effectiveness.

  17. [17]
    World Anti-Doping Agency. “2027 Prohibited List.” 2027. LinkReview

    Published September 21, 2026; effective January 1, 2027. S0 explicitly mentions peptides. The 2026 List remains in force through December 31, 2026.

  18. [18]
    Fischer Munch H, Just R, Mosolff Mathiesen J, et al.. “Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.” J Med Chem. 2025. DOI PubMedAnimal study

    Published petrelintide-specific development and preclinical pharmacology. Does not establish human efficacy; earlier profile text incorrectly called this package unpublished.


Medical disclaimer

Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research, clinical trial data, and company disclosures. It is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Petrelintide is an investigational drug that is not FDA-approved and is not available by prescription. It is only accessible through clinical trial enrollment. Always consult a qualified healthcare provider before making decisions about any medication or clinical trial participation.